Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.23736/S2724-6051.22.04861-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Complication rate across the minimally invasive surgical treatments (MISTs): where do we stand? A systematic review of the literature.
Prostate Cancer Prostatic Dis
October 2024
Oncologic Minimally Invasive Urology and Andrology Unit, Department of Experimental and Clinical Medicine, Careggi Hospital, University of Florence, 50121, Florence, Italy.
Background: Over the past decade, the range of surgical options to benign prostatic obstruction (BPO) has expanded significantly with the advent of minimally invasive surgical therapies (MISTs). Nevertheless, the available evidence in the field is heterogeneous. Efficacy and safety thresholds are yet to be determined.
View Article and Find Full Text PDFCan Rezum stand out as the most versatile and better performing minimally invasive treatment for the management of LUTS related to BPH?
Minerva Urol Nephrol
October 2022
Department of Urology, Villa Stuart Private Hospital, Rome, Italy.
[Minimally Invasive Therapy: What Is The Status In 2021 - What's Coming, What's Going?].
Aktuelle Urol
June 2022
Medizinische Fakultät, Klinik für Urologie, Universitätsklinikum Freiburg, Freiburg, Germany.
Due to the large number of men affected and a variable clinical presentation, the widespread disease "benign prostatic syndrome" requires individual treatment options tailored to the patient's specific clinical characteristics and wishes. If surgical treatment is indicated, there is a wide range of invasive procedures available. For a long time, transurethral resection of the prostate and simple prostatectomy were considered the gold standard, but these procedures are associated with increased morbidity and limitations in sexual function.
View Article and Find Full Text PDFThe role of novel minimally invasive treatments for lower urinary tract symptoms associated with benign prostatic hyperplasia.
BJU Int
September 2020
Department of Urology, St. Antonius Hospital, Gronau, Germany.
Objectives: To provide an update on novel minimally invasive lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) treatments in a non-systematic review. To define potential target populations for the various new minimally invasive treatments.
Methods: Recent literature, meta-analyses and guideline recommendations for aquablation (AquaBeam ; PROCEPT BioRobotics, Redwood City, CA, USA), water vapour thermal therapy (Rezūm ; Boston Scientific, Natick, MA, USA), prostate artery embolisation (PAE), prostatic urethral lift (UroLift ; NeoTract-Teleflex, Pleasanton, CA, USA) and the temporary implantable nitinol device [i-TIND (nitinol butterfly-like stent ); Medi-Tate Ltd.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!